| Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights |
Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025 FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2025. Lindsay A. |
globenewswire.com |
2025-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference |
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the following sessions at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference, taking place on Tuesday, May 13, 2025: |
globenewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript |
Fortress Biotech, Inc. (NASDAQ:FBIO ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - CFO Srinivas Sidgiddi - VP, R&D Louis Donati - Director, Market Access Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - ROTH Capital Kalpit Patel - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2025-03-26 21:39:53 |
Czytaj oryginał (ang.) |
| Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform |
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic collaboration aimed at identifying and evaluating biopharmaceutical compounds using artificial intelligence (AI) for potential acquisition or licensing by Fortress. |
globenewswire.com |
2025-03-17 10:55:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT |
Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors |
globenewswire.com |
2025-01-27 10:30:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease |
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium also retains ownership over any Priority Review Voucher that may be issued at NDA approval MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the acceptance for review of the New Drug Application (“NDA”) by the U.S. Food and Drug Administration (“FDA”) for CUTX-101 (Copper Histidinate) for the treatment of Menkes disease, a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A. The NDA has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2025. |
globenewswire.com |
2025-01-06 10:00:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights |
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous squamous cell carcinoma MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2024. Lindsay A. |
globenewswire.com |
2024-11-14 18:10:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech to Participate in October 2024 Investor Conferences |
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the following upcoming October 2024 investor conferences: |
globenewswire.com |
2024-09-26 12:30:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements |
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that on September 19, 2024 it entered into securities purchase agreements with healthcare focused institutional investors for the issuance and sale of 3,939,394 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering at a purchase price of $1.65 per share. In a concurrent private placement, the Company also agreed to issue to the same investors warrants to purchase up to 3,939,394 shares of common stock. The private placement warrants have an exercise price of $1.84 per share, will be exercisable commencing six months from the date of issuance, and will expire five and one-half years following the date of issuance. |
globenewswire.com |
2024-09-20 12:30:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference |
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference. |
globenewswire.com |
2024-09-04 12:30:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights |
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults |
globenewswire.com |
2024-08-13 20:05:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 |
Extends maturity of long-term debt as Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 Extends maturity of long-term debt as Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 |
globenewswire.com |
2024-07-25 12:30:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock |
MIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that its Board of Directors has paused the payment of dividends on the Company's 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Stock”) until further notice. In accordance with the terms of the Series A Preferred Stock, dividends on the Series A Preferred Stock will continue to accrue and cumulate until such dividends are authorized or declared. |
globenewswire.com |
2024-07-05 20:05:00 |
Czytaj oryginał (ang.) |
| Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript |
Fortress Biotech, Inc. (NASDAQ:FBIO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Co-Founder President and Chief Executive Officer Ernie De Paolantonio - Chief Financial Officer Ramsey Alloush - General Counsel Srinivas Sidgiddi - Vice President of Clinical Development and Medical Affairs Conference Call Participants Scott Henry - ROTH Capital Partners Brandon Folkes - Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Journey Medical's Third Quarter 2022 Financial Results and Corporate Update Conference Call. |
seekingalpha.com |
2022-11-11 00:42:05 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript |
Journey Medical Corporation (NASDAQ:FBIO ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Claude Maraoui - Co-Founder President and Chief Executive Officer Ernest De Paolantonio - Chief Financial Officer Ramsey Alloush - General Counsel Dr. Srinivas Sidgiddi - Vice President of Clinical Development and Medical Affairs Conference Call Participants Brandon Folkes - Cantor Fitzgerald Mayank Mamtani - B. Riley FBR Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2022-08-10 01:05:12 |
Czytaj oryginał (ang.) |
| Fortress Biotech (FBIO) Investor Presentation - Slideshow |
The following slide deck was published by Fortress Biotech, Inc. in conjunction with this event.. |
seekingalpha.com |
2020-09-04 21:09:15 |
Czytaj oryginał (ang.) |
| Fortress Biotech Investor Presentation - Slideshow |
The following slide deck was published by Fortress Biotech, Inc. in conjunction with this event.. |
seekingalpha.com |
2020-08-28 12:41:58 |
Czytaj oryginał (ang.) |
| The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares |
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune ... |
finance.yahoo.com |
2020-01-17 15:07:09 |
Czytaj oryginał (ang.) |